Kei-Lai Fong

This inventor holds 5 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignee: Synchroneuron, Inc.. Active years: 2016-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kei-Lai Fong. Retrieved from https://idiyas.com/inventor/kei-lai-fong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 43(Granted Patents)

Location History:

Berkeley, CA (US) (2016)
Duxbury, MA (US) (2019)

Company Filing History:

5 out of 15

Synchroneuron, Inc.

patents

Years Active: 2016-2019

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10512621 - Methods of treating posttraumatic stress disorder with acamprosate salts (2019-12-24),

2. 10166207 - Acamprosate formulations, methods of using the same, and combinations comprising the same (2019-01-01),

3. 9427420 - Acamprosate formulations, methods of using the same, and combinations comprising the same (2016-08-30),

4. 9421179 - Acamprosate formulations, methods of using the same, and combinations comprising the same (2016-08-23),

5. 9421178 - Acamprosate formulations, methods of using the same, and combinations comprising the same (2016-08-23),

Title: The Innovations of Kei-Lai Fong: Pioneering Patents in PTSD Treatment

Introduction: Kei-Lai Fong, an innovative inventor based in Berkeley, California, has made significant contributions to the field of mental health treatment through her groundbreaking patents. With a total of five patents to her name, she is a noteworthy figure in the realm of medical research and therapeutic methods.

Latest Patents: Kei-Lai Fong's latest patents focus on the treatment of posttraumatic stress disorder (PTSD) using acamprosate salts. The embodiments disclosed in these patents relate to methods of treating PTSD by using acamprosate formulations, particularly in combination with other medications. This pioneering approach aims to enhance the efficacy of treatments for individuals suffering from PTSD, employing acamprosate formulations alongside neuroleptic (antipsychotic) and antidepressant drugs. The innovative methods and compositions detailed in her patents have the potential to revolutionize the way PTSD is treated.

Career Highlights: Fong is currently associated with Synchroneuron, Inc., a company dedicated to advancing neuroscience and mental health solutions. Her academic and professional journey reflects her deep commitment to improving therapeutic options for mental health patients through research and innovation.

Collaborations: Throughout her career, Kei-Lai Fong has collaborated with esteemed colleagues such as Barry S. Fogel and William D. Kerns. These partnerships have facilitated a dynamic exchange of ideas and expertise, further enhancing her contributions to her field.

Conclusion: Kei-Lai Fong's work exemplifies the importance of innovation in addressing pressing mental health challenges. Her patents, particularly in the realm of PTSD treatment, mark significant strides toward improving the lives of countless individuals affected by this condition. Through her collaboration and dedication, Fong continues to pave the way for future advancements in mental health therapies.

Profile summary based on public USPTO records.